Fraga Carlos A M, Barreiro Eliezer J
Laboratório de Avaliacao e Síntese de Substâncias Bioativas, Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, PO Box 68006, Zip Code 21944-971, Rio de Janeiro, RJ, Brazil.
Curr Med Chem. 2006;13(2):167-98. doi: 10.2174/092986706775197881.
In this article we provide an overview on the medicinal chemistry of new bioactive N-acylhydrazone (NAH) derivatives designed through the structural optimization of N-arylhydrazone precursors, originally planned by molecular hybridization of two known 5-lipoxygenase inhibitors, i.e. CBS-1108 and BW-755c. The analgesic, antiedematogenic and platelet anti-aggregating profile of several isosteric NAH compounds was investigated by using classical in vivo and ex-vivo pharmacological assays, which allowed the identification of new potent centrally and peripherically-acting analgesic leads, new antiinflammatory agents and new antithrombotic prototypes. During this study, dozens of active NAH compounds were discovered, clarifying the structure-activity relationships for this series of derivatives and indicating the pharmacophoric character of the N-acylhydrazone moiety for its biological profile.
在本文中,我们概述了新型生物活性N-酰腙(NAH)衍生物的药物化学,这些衍生物是通过对N-芳基腙前体进行结构优化设计而成的,最初是通过将两种已知的5-脂氧合酶抑制剂即CBS-1108和BW-755c进行分子杂交设计的。通过经典的体内和体外药理学试验研究了几种等排体NAH化合物的镇痛、抗水肿和血小板抗聚集特性,从而鉴定出了新型强效的中枢和外周作用镇痛先导物、新型抗炎剂和新型抗血栓原型。在这项研究中,发现了数十种活性NAH化合物,阐明了该系列衍生物的构效关系,并指出了N-酰腙部分对其生物学特性的药效团特征。